Results from LightTouch trials expected to be disclosed on March 24-27 meeting (PINK:GTHP), (OTC:GTHP)

LightTouch™ is a non-invasive medical device that can detect cervical cancer. The device has been developed by Guided Therapeutics, Inc. (PINK and OTC:GTHP.PK). This device is capable of detecting cervical cancer in its early stages without causing any pain to the patient. Its detection method is also very fast and free from bias. It is also different from other HPV and Pap tests that need tissues of the patient and thus cause a lot of pain. The company wants to bring this device into the market of the United States of America. For this purpose, it submitted a Premarket Approval (PMA) application to the country’s toughest regulator – the Food and Drug Administration (FDA) – on December 10, 2008. After that, the company started conducting “FDA pivotal” clinical trials to measure the safety and the effectiveness of LightTouch. On February 23, 2010, the company announced that the results from these trials will be disclosed at the upcoming meeting of the American Society for Colposcopy and Cervical Pathology. This meeting is expected to take place from March 24 to 27 in Las Vegas.

The FDA pivot trials took place in six different clinics of the United States. About 2000 women participated in those trials. According to the company, the trial showed that LightTouch can detect cancerous and pre cancerous cells in the cervix by passing light onto the cervix and then by studying the wavelengths of the reflected light.

In the American Society meeting, the study results will be disclosed though a series of 5 peer-to-peer presentations titled as “Multimodal Spectroscopy as a Triage Test for Women at risk for Cervical Neoplasia: Results of a 1607 Subject Pivotal Trial”, “Multimodal Spectroscopy as a Triage Test for Women at risk for Cervical Neoplasia: Results for Adolescent Subjects”, “Multimodal Spectroscopy as a Triage Test for Women at risk for Cervical Neoplasia: Hispathology Review Procedures and Results”, “Multimodal Spectroscopy as a Triage Test for Women at risk for Cervical Neoplasia: Results of Follow Up Data” and “Multimodal Spectroscopy as a Triage Test for Women at risk for Cervical Neoplasia: Experience with a Low Cost Commercial Prototype”. All these presentations will be done by 5 eminent American doctors.

Apart from the presentations, the company is also planning to display a real LightTouch device. All the components of the device, such as the user interface and the one-time use calibration, will also be presented.